Prolonged hyperalimentation in catabolic chronic dialysis therapy patients.
Plasma concentrations of 25 essential (EAA) and nonessential (NEAA) amino acids were measured pre- and postdialysis in 46 chronic hemodialysis therapy (CDT) patients. Sixteen of these patients with prior weight loss of 14.5 +/- 2.37 pounds in 24 months were administered a GAA solution (EAA + NEAA + glucose) for 20 weeks during each dialysis. Eight of these patients (group 1) responded with improved appetite and weight gain; the remaining eight patients (group 2) with clinically advanced metabolic bone disease continued to lose weight. Five other patients (group 14), biochemically similar to group 1 but with shorter prior dialysis experience, who received EAA (plus glucose) hyperalimentation (including oral I-histidine), experienced weight gain similar to group 1 but displayed significantly different plasma aminograms indicating a deficit of NEAA. When EAA and glucose hyperalimentation was administered without histidine (1 patient) no weight gain occurred and aminograms differed significantly from other groups. Plasma aminograms of 25 weight-stable, nonhyperalimented CDT patients were obtained for comparison. Results indicate GAA hyperalimentation can promote weight gain in catabolic CDT patients with inadequate prior nutritional intake (as in groups 1 and 14) but cannot reverse weight loss when the primary clinical setting is advanced metabolic bone disease and myopathy due to hyperparathyroidism (group 2). Hyperalimentation with glucose and an amino acid solution specifically tailored to the needs of CDT patients may improve results. Plasma phosphoethanolamine levels, normal for weight-stable and elevated in catabolic CDT patients, suggest a possible role for phosphoethanolamine as a marker for catabolism.
D000596:Amino Acids / Q000008:administration & dosage* / Q000097:blood; D001835:Body Weight; D001851:Bone Diseases, Metabolic / Q000097:blood / Q000209:etiology; D005947:Glucose / Q000008:administration & dosage; D006639:Histidine / Q000008:administration & dosage; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology; D007674:Kidney Diseases / Q000097:blood / Q000628:therapy*; D009747:Nutritional Physiological Phenomena; D010281:Parathyroid Hormone / Q000097:blood; D010288:Parenteral Nutrition / Q000379:methods*; D010289:Parenteral Nutrition, Total / Q000379:methods*; D006435:Renal Dialysis
D000596:Amino Acids; D010281:Parathyroid Hormone; D006639:Histidine; D005947:Glucose